WO2009017719A8 - Modulateurs du récepteur ccr9 et leurs procédés d'utilisation - Google Patents

Modulateurs du récepteur ccr9 et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2009017719A8
WO2009017719A8 PCT/US2008/009142 US2008009142W WO2009017719A8 WO 2009017719 A8 WO2009017719 A8 WO 2009017719A8 US 2008009142 W US2008009142 W US 2008009142W WO 2009017719 A8 WO2009017719 A8 WO 2009017719A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulators
ccr9 receptor
compounds
ccr9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/009142
Other languages
English (en)
Other versions
WO2009017719A2 (fr
WO2009017719A3 (fr
Inventor
Eric C. Anderson
Ronald J. Biediger
Jie Chen
Brian Dupre
Pedro Lory
Robert V. Market
Keith A. Monk
Michael M. Savage
Reginald Tennyson
Brandon M. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Encysive Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc filed Critical Encysive Pharmaceuticals Inc
Priority to AU2008282903A priority Critical patent/AU2008282903B2/en
Priority to MX2010001187A priority patent/MX2010001187A/es
Priority to CA2692013A priority patent/CA2692013C/fr
Priority to EP08794832A priority patent/EP2220065A2/fr
Publication of WO2009017719A2 publication Critical patent/WO2009017719A2/fr
Publication of WO2009017719A3 publication Critical patent/WO2009017719A3/fr
Anticipated expiration legal-status Critical
Publication of WO2009017719A8 publication Critical patent/WO2009017719A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention propose des composés qui sont des modulateurs de l'activité du récepteur CCR9, des compositions contenant les composés et des procédés d'utilisation des composés et des compositions. Dans certains modes de réalisation, l'invention propose des procédés pour traiter ou améliorer des maladies associées à la modulation de l'activité du récepteur CCR9.
PCT/US2008/009142 2007-07-30 2008-07-28 Modulateurs du récepteur ccr9 et leurs procédés d'utilisation Ceased WO2009017719A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008282903A AU2008282903B2 (en) 2007-07-30 2008-07-28 Modulators of CCR9 receptor and methods of use thereof
MX2010001187A MX2010001187A (es) 2007-07-30 2008-07-28 Moduladores del receptor ccr9 y metodos para su uso.
CA2692013A CA2692013C (fr) 2007-07-30 2008-07-28 Modulateurs du recepteur ccr9 et leurs procedes d'utilisation
EP08794832A EP2220065A2 (fr) 2007-07-30 2008-07-28 Modulateurs du recepteur ccr9 et procedes de leur utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96264007P 2007-07-30 2007-07-30
US60/962,640 2007-07-30

Publications (3)

Publication Number Publication Date
WO2009017719A2 WO2009017719A2 (fr) 2009-02-05
WO2009017719A3 WO2009017719A3 (fr) 2009-04-23
WO2009017719A8 true WO2009017719A8 (fr) 2010-02-11

Family

ID=40305125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009142 Ceased WO2009017719A2 (fr) 2007-07-30 2008-07-28 Modulateurs du récepteur ccr9 et leurs procédés d'utilisation

Country Status (7)

Country Link
EP (1) EP2220065A2 (fr)
KR (1) KR20100033418A (fr)
AU (1) AU2008282903B2 (fr)
CA (1) CA2692013C (fr)
MX (1) MX2010001187A (fr)
SG (1) SG183667A1 (fr)
WO (1) WO2009017719A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
US9221787B2 (en) * 2010-10-12 2015-12-29 Zafgen, Inc. Sulphonamine compounds and methods of making and using same
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
CN118201912A (zh) * 2021-10-28 2024-06-14 四国化成工业株式会社 噻吩化合物、其合成方法和包含所述噻吩化合物的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016520A1 (fr) * 1996-10-16 1998-04-23 American Cyanamid Company Preparation d'acides ortho-sulfonamido heteraryl-hydroxamiques et leur utilisation en tant qu'inhibiteurs des metalloproteinases matricielles et de tace
JP3972163B2 (ja) * 1999-06-18 2007-09-05 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists

Also Published As

Publication number Publication date
KR20100033418A (ko) 2010-03-29
WO2009017719A2 (fr) 2009-02-05
CA2692013A1 (fr) 2009-02-05
AU2008282903A1 (en) 2009-02-05
CA2692013C (fr) 2012-08-28
WO2009017719A3 (fr) 2009-04-23
SG183667A1 (en) 2012-09-27
MX2010001187A (es) 2010-03-04
AU2008282903B2 (en) 2011-06-30
EP2220065A2 (fr) 2010-08-25

Similar Documents

Publication Publication Date Title
NL301145I1 (fr)
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
WO2009044173A3 (fr) Procédés de traitement du cancer à l'aide d'inhibiteurs de la voie de notch
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TW200716624A (en) Compounds for modulating TRPV3 function
WO2007109330A3 (fr) Composés modulant le récepteur de la sip
UA98629C2 (ru) Соединения и способ модуляции киназ
SG10201811584RA (en) Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
WO2007056124A3 (fr) Composés destinés à moduler la fonction de trpv3
WO2010021693A3 (fr) Modulateurs de mif
WO2010031056A3 (fr) Procédés et compositions pour moduler l'activité ire1, src, et abl
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
IL192868A0 (en) 1,4-di substituted 3-cyano- pyridone perivatives and their use as positive mglur2-receptor modulators
MX2010002028A (es) Metodos y composiciones para modular celulas t.
WO2010068710A3 (fr) Composés inhibiteurs de kinase
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
EP2155705A4 (fr) Compositions permettant de réguler ou de moduler la détection du quorum dans une bactérie, procédés d'utilisation de ces composés et procédés de régulation et de modulation de la détection du quorum dans une bactérie
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2692013

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008282903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008794832

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 20107001995

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010519223

Country of ref document: JP

Ref document number: MX/A/2010/001187

Country of ref document: MX

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2008282903

Country of ref document: AU

Date of ref document: 20080728

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1285/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase in:

Ref country code: JP